dactinomycin and nutlin-3a

dactinomycin has been researched along with nutlin-3a in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (25.00)	29.6817
2010's	8 (66.67)	24.3611
2020's	1 (8.33)	2.80

Authors

Authors	Studies
Giono, LE; Manfredi, JJ	1
Hosoi, H; Iehara, T; Kakazu, N; Katsumi, Y; Kikuchi, K; Miyachi, M; Tsubai-Shimizu, S; Tsuchiya, K; Yagyu, S	1
Choong, ML; Lane, DP; Lee, MA; Yang, H	1
Campbel, J; Higgins, M; Lain, S; Lane, DP; Rao, B; Thompson, AM; van Leeuwen, IM	1
Brown, CJ; Campbell, J; Higgins, M; Laín, S; McCarthy, AR; Pirrie, L; van Leeuwen, IM; Westwood, NJ	1
Laín, S; Rao, B; Sachweh, MC; van Leeuwen, IM	1
Lain, S; Rao, B; Thompson, AM	1
Gdowicz-Kłosok, A; Krześniak, M; Rusin, M; Ścieglińska, D; Zajkowicz, A	1
Almacellas, E; Ambrosio, S; Cortes, CL; Ferreres, JC; Hernández-Losa, J; Kozma, SC; Tauler, A; Thomas, G; Veiga, SR	1
Bender, S; Jones, DT; Kool, M; Korshunov, A; Kulozik, AE; Lichter, P; Milde, T; Müller, S; Pajtler, KW; Peter Collins, V; Pfister, SM; Schlotter, M; Tzaridis, T; Witt, H; Witt, O; Wittmann, A	1
Gdowicz-Kłosok, A; Krześniak, M; Rusin, M; Zajkowicz, A; Łasut, B	1
Gdowicz-Kłosok, A; Głowala-Kosińska, M; Krześniak, M; Rusin, M; Zajkowicz, A; Łasut-Szyszka, B	1

Reviews

1 review(s) available for dactinomycin and nutlin-3a

Article	Year
p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy. British journal of cancer, 2013, Dec-10, Volume: 109, Issue:12 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dactinomycin; Female; Genome; Humans; Imidazoles; Phosphorylation; Piperazines; Tumor Suppressor Protein p53	2013

Article

Year

p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy.

British journal of cancer, 2013, Dec-10, Volume: 109, Issue:12

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dactinomycin; Female; Genome; Humans; Imidazoles; Phosphorylation; Piperazines; Tumor Suppressor Protein p53

2013

Other Studies

11 other study(ies) available for dactinomycin and nutlin-3a

Article	Year
Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest. Molecular and cellular biology, 2007, Volume: 27, Issue:11 Topics: Animals; Antibiotics, Antineoplastic; Cell Cycle; Cell Line; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Dactinomycin; Doxorubicin; Humans; Imidazoles; Piperazines; Protein Binding; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-mdm2; Response Elements; RNA, Small Interfering; Tumor Suppressor Protein p53	2007
Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jun-15, Volume: 15, Issue:12 Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dactinomycin; Drug Synergism; Humans; Imidazoles; Mutation, Missense; Neoplasms, Muscle Tissue; Piperazines; Proto-Oncogene Proteins c-mdm2; Rhabdomyosarcoma; Tumor Suppressor Protein p53; Vincristine	2009
Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell cycle (Georgetown, Tex.), 2009, Sep-01, Volume: 8, Issue:17 Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Dactinomycin; Gene Expression Profiling; Humans; Imidazoles; Phosphorylation; Piperazines; Time Factors; Tumor Suppressor Protein p53	2009
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget, 2010, Volume: 1, Issue:7 Topics: Aneugens; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytoprotection; Dactinomycin; Dose-Response Relationship, Drug; Gene Knockout Techniques; Genes, p53; HCT116 Cells; Humans; Imidazoles; Neoplasms; Piperazines; Protein Serine-Threonine Kinases	2010
Mechanism-specific signatures for small-molecule p53 activators. Cell cycle (Georgetown, Tex.), 2011, May-15, Volume: 10, Issue:10 Topics: Cell Line, Tumor; Dactinomycin; Humans; Imidazoles; Piperazines; Proto-Oncogene Proteins c-mdm2; RNA, Messenger; Tumor Suppressor Protein p53	2011
An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells. Cell cycle (Georgetown, Tex.), 2012, May-01, Volume: 11, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Count; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Cytarabine; Dactinomycin; Drug Screening Assays, Antitumor; Fatty Acids, Unsaturated; Fibroblasts; HCT116 Cells; Humans; Imidazoles; Piperazines; Tumor Suppressor Protein p53; Vinblastine; Vinca Alkaloids; Vinorelbine	2012
Actinomycin D and nutlin-3a synergistically promote phosphorylation of p53 on serine 46 in cancer cell lines of different origin. Cellular signalling, 2015, Volume: 27, Issue:9 Topics: Cell Line, Tumor; Dactinomycin; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-mdm2; Serine; Tumor Suppressor Protein p53	2015
Effect of low doses of actinomycin D on neuroblastoma cell lines. Molecular cancer, 2016, Jan-04, Volume: 15 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Dactinomycin; Dose-Response Relationship, Drug; Drug Synergism; Female; Hydroxamic Acids; Imidazoles; Mice; Neuroblastoma; Piperazines; Proto-Oncogene Proteins c-myc; Time Factors; Tumor Suppressor Protein p53; Vorinostat	2016
Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. Oncotarget, 2016, Sep-20, Volume: 7, Issue:38 Topics: Animals; Apoptosis; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dactinomycin; DNA Mutational Analysis; Ependymoma; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Immunohistochemistry; Medulloblastoma; Mice; Neurons; Piperazines; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-mdm2; Stem Cells; Transcription Factor RelA; Treatment Outcome; Tumor Suppressor Protein p53	2016
PIM2 survival kinase is upregulated in a p53-dependent manner in cells treated with camptothecin or co-treated with actinomycin D and nutlin-3a. Archives of biochemistry and biophysics, 2018, 10-01, Volume: 655 Topics: Amino Acid Sequence; Apoptosis; bcl-Associated Death Protein; Camptothecin; Cell Line, Tumor; Dactinomycin; Drug Synergism; Gene Knockdown Techniques; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Nerve Tissue Proteins; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA, Long Noncoding; RNA, Messenger; Serine; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53; Up-Regulation	2018
Synergistic activation of p53 by actinomycin D and nutlin-3a is associated with the upregulation of crucial regulators and effectors of innate immunity. Cellular signalling, 2020, Volume: 69 Topics: A549 Cells; Antibiotics, Antineoplastic; Dactinomycin; Humans; Imidazoles; Immunity, Innate; Lung Neoplasms; Piperazines; Pyroptosis; Transcriptional Activation; Tumor Suppressor Protein p53	2020